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Objectives In this study we tested the hypothesis that lipopolysaccharide-binding protein (LBP) might be able to be used as
a biomarker for coronary artery disease (CAD).
Background The mechanisms by which the innate immune recognition of pathogens could lead to atherosclerosis remain
unclear. Lipopolysaccharide-binding protein is the first protein to encounter lipopolysaccharide and to deliver it
to its cellular targets, toll-like receptors; therefore, its presence might be a reliable biomarker that indicates acti-
vation of innate immune responses.
Methods A total of 247 men undergoing elective coronary angiography were studied, and the extent of coronary athero-
sclerosis was assessed by 2 established scores: “extent score” and “severity score.” Levels of LBP, markers of
inflammation, and traditional risk factors for CAD were assessed.
Results Serum LBP concentration was significantly increased in 172 patients with angiographically confirmed CAD com-
pared with 75 individuals without coronary atherosclerosis (20.6  8.7 pg/ml vs. 17.1  6.0 pg/ml, respectively;
p  0.002). Moreover in multivariable logistic regression analyses, adjusted for established cardiovascular risk
factors and markers of systemic inflammation, LBP was a significant and independent predictor of prevalent
CAD (p  0.05 in all models).
Conclusions Lipopolysaccharide-binding protein might serve as a novel marker for CAD in men. The present results underlie
the potential importance of innate immune mechanisms for CAD. Further studies are warranted to bolster the
data and to identify pathogenetic links between innate immune system activation and atherosclerosis. (J Am
Coll Cardiol 2007;50:25–31) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.070g
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ctherosclerosis can be regarded as a chronic inflammatory
esponse limited to the vascular bed (1). New insights into
he pathogenesis of atherosclerosis clearly indicate that
ultiple factors, such as hypertension, high plasma concen-
rations of low-density lipoprotein (LDL) cholesterol, dia-
etes mellitus, and infection, influence the development and
rogression of atherosclerosis (2).
Although the inflammatory nature of the disease is widely
ccepted, what initiates and maintains this inflammatory
tate remains unclear. Microbial infections seem to promote
yocardial infarction (3). Epidemiologic evidence has sug-
rom the *Department of Intensive Care Medicine, University Hospital of Bern
Inselspital), Bern, Switzerland; †Department of Internal Medicine II, University of
lm, Ulm, Germany; ‡Infection and Immunity Group, University of Sussex,
righton, United Kingdom; §Institute of Medical Statistics and Epidemiology,
echnical University of Munich, Munich, Germany; Section of Experimental
naesthesiology, University of Ulm, Ulm, Germany; and the #Department of
ephrology, Technical University of Munich, Munich, Germany. The first three
uthors contributed equally to this work.b
Manuscript received November 27, 2006; revised manuscript received January 11,
007, accepted February 5, 2007.ested a link between microbial infection and atherosclerosis
4–6). In particular, it is possible that lipopolysaccharide
LPS) from bacteria such as Chlamydia pneumonia (7–9),
elicobacter pylori (10,11), or Porphyromonas gingivalis
6,12) may be triggering the inflammatory response that
eads to atherogenesis. The question that remains is how
hese microbial pathogens trigger this inflammatory disease.
he recent discovery of toll-like receptors (TLRs), which
re the key microbial sensors of the innate immune system
13), in atherosclerotic lesions (14) provides a mechanistic
ink between infection, innate immune recognition, inflam-
ation, and atherosclerosis.
The detection of microbial infection and the initiation of
he innate immune response rely on TLRs, which recognize
icrobial “signatures.” Ligation of TLRs results in the
ecruitment of an adaptor protein, myeloid differentiation
actor 88 (MyD88), which finally leads to activation of
uclear factor B and the production of proinflammatory
ytokines. A link between TLRs and atherosclerosis has
een suggested in studies where expression of TLR-1, -2,
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Lipopolysaccharide-Binding Protein and CAD July 3, 2007:25–31and -4 was found in atheroscle-
rotic lesions (14,15) as well as in
studies where loss of TLR-4 or
MyD88 reduced disease severity
in atherosclerosis (16,17).
Thus it is emerging that LPS
from various gram-negative bac-
teria might lead to the initiation
of events that lead to the recruit-
ment of inflammatory cells into
atherosclerotic lesions (9,11,18).
Many of the steps involved in the
interaction of lipopolysaccharides
(LPS) with monocytes and endo-
thelial cells have been revealed in
the last 2 decades: LPS binds to
lipopolysaccharide-binding pro-
tein (LBP) (19,20), and LPS/LBP
complexes are delivered to CD14
(21) which in turn interacts with
LRs. The detection of LPS stimulates the synthesis of
nterleukins, growth factors, and cytokines with the poten-
ial to exert proinflammatory and proatherogenic activities
22,23). Therefore it seems that the mammalian “LPS-
ensing” apparatus consists of different receptors, membrane
ound and soluble, that cooperate to induce activation
eading to the secretion of proinflammatory cytokines (24).
ipopolysaccharide-binding protein not only is a serum pro-
ein but also intercalates into cell membranes and assumes a
ransmembrane configuration (25). Thus, LBP is present as
cell-surface protein even under serum-free conditions and
n this configuration is involved in cell signaling (26).
Because LBP is the first protein to encounter LPS and to
eliver it to its cellular targets, it seems to be the first step in
his proinflammatory cascade (23); therefore, its presence
ight be a reliable biomarker that indicates activation of
nnate immune responses. It might qualify as an excellent
arker for activation of innate immunity.
Owing to the economic burden and often devastating
onsequences for the individual caused by the sequelae of
therosclerosis, it is highly desirable to have reliable biomar-
ers for the development and/or progression of atheroscle-
osis. In the past, several markers have been discussed, and
-reactive protein (CRP) has been proposed as a reliable
arker for atherosclerosis (27). Because LBP is similar to
RP, both being acute-phase proteins, we tested the
ypothesis that LBP might be able to be used as a
iomarker for coronary artery disease (CAD).
ethods
atients undergoing coronary angiography. A total of
47 male patients, ages 31 to 83 years (mean age 61.1 
0.1 years), who were undergoing elective coronary angiog-
aphy at the University Hospital, Heidelberg, were studied.
Abbreviations
and Acronyms
BMI  body mass index
ES  extent score
FPG  fasting plasma
glucose
HDL  high-density
lipoprotein
HOMA  homeostasis
model assessment
LBP  lipopolysaccharide-
binding protein
LDL  low-density
lipoprotein
LPS  lipopolysaccharide
TLR  toll-like receptor
VLDL  very low-density
lipoproteinerum samples were obtained before angiography and orozen at 70°C until analyses were performed. The design
nd methods of the study have been reported previously
28,29).
Examinations of angiograms were performed by 2 inde-
endent investigators, who were blinded to risk factors and
BP serum levels. The extent of angiographically docu-
ented CAD was quantified as follows: 1) the “severity
core” (SS) as 1-, 2-, or 3-vessel disease, defined as stenosis
f more than 50% of the luminal diameter in 1, 2, or 3
oronary arteries or their major branches (30); and 2) the
extent score” (ES), in which atherosclerotic wall irregular-
ties in 10 defined segments of the coronary arteries are
aken into account. The ES has been shown to correlate
etter with risk factors of CAD than other scores (31). The
S was 0 to 100 points, and prevalent CAD was defined as
S 0. Coronary artery disease was found in 172 patients
47 had 1-vessel, 57 had 2-vessel, and 68 had 3-vessel
isease).
ontrol subjects. The control group consisted of: 1) 20
atients with fibromyalgia, a noninflammatory disorder of
ones and joints (32,33); and 2) 20 septic patients without
uspected or known CAD. Diagnosis of primary fibromy-
lgia was accomplished according to the American College
f Rheumatology criteria (34). Criteria for inclusion in the
rial were the presence of a “jump sign” in at least half of the
8 tender points examined by applying 4 kg pressure with
he thumb and the absence of depression as assessed by
eck’s Depression Inventory (19 points). None of the
atients belonged to a group with depression or so-called
omatization. All septic patients fulfilled the sepsis cri-
eria of the 2001 International Sepsis Definitions Con-
erence (35).
None of the study participants, except the septic patients,
ad any of the following disorders, associated with an
cute-phase reaction: febrile acute infection or acute state of
chronic infection or an inflammatory disease; underlying
ematologic or malignant diseases, severe liver and renal
isorders, and surgery within the previous 4 weeks. Current
edication and sociodemographic characteristics were also
ecorded.
Participation was voluntary, and written informed con-
ent was obtained from each subject upon entry into the
tudy. The study was approved by the ethics committee of
he University of Heidelberg (for patients with fibromyalgia
nd sepsis the study was approved by the University of Ulm
thics committee).
aboratory methods. Venous blood was drawn in CAD
nd fibromyalgia patients after an overnight fasting period
nder standardized conditions. In septic patients, blood was
rawn at various times of the day. Within 30 min after
enipuncture, the remaining blood was centrifuged at
,000 g for 10 min, immediately aliquoted and frozen at
70°C until further analysis. No specimen was inadver-
ently thawed during storage.
BP. Serum was stored at 70°C and thawed on 1
ccasion to perform tests. The LBP was determined from
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July 3, 2007:25–31 Lipopolysaccharide-Binding Protein and CADerum samples and controls using standardized enzyme-
inked immunosorbent assay (ELISA) methods (Hycult
iotechnology, Uden, the Netherlands), and serum from
normal control subjects was used for interassay varia-
ion. Both the intra- and the interassay coefficients of
ariation were 5.0%.
ytokine assays. The following markers of inflammation
nd hemostasis were determined by ELISA in patients’ sera:
nterleukin-6 (Quantikine, R&D Systems, Wiesbaden,
ermany) and plasma concentrations of CRP in a highly
ensitive assay (hsCRP; Dade Behring, Cupertino,
alifornia).
nalysis of lipids/lipoproteins. Total cholesterol, high-
ensity lipoprotein (HDL) cholesterol, and triglyceride
oncentrations were determined enzymatically with a Syn-
hron LX-20 (Beckman Coulter, Munich, Germany). The
DL and very low-density lipoprotein (VLDL) were sep-
rated by ultracentrifugation in a Beckman LM-8 ultracen-
rifuge in 100-l volumes with a VT-51.2 rotor (Beckman
oulter). The atherogenic index was calculated using the
ollowing formula: (total cholesterol  HDL cholesterol)/
DL cholesterol.
ssessment of insulin resistance. Serum insulin immuno-
eactivity was determined from frozen serum by ELISA
CIS Bio International, Gif-Sur-Yvette, France). Plasma
lucose was measured by a glucose-oxidase method. The
egree of insulin resistance was estimated by homeostasis
odel assessment (HOMA) according to the method de-
cribed by Matthews et al. (36). In particular, an insulin
esistance score (HOMA-IR) was computed with the fol-
owing formula: fasting serum glucose (mmol/l)  fasting
erum insulin (U/ml)/22.5.
tatistical analysis. Statistical analyses were performed
sing SPSS software version 11.0 (SPSS Inc., Chicago,
llinois). Because serum levels of LBP showed a skewed
istribution, Spearman correlation coefficients were used to
escribe the association between LBP and the continuous
ariables of interest. After adjustment for age and body mass
ndex (BMI), Partial Spearman correlation coefficients were
alculated for LBP, hsCRP, interleukin-6, fasting plasma
lucose (FPG), HOMA-IR, pack-years smoking, ES, SS,
nd blood lipids, such as HDL, LDL, VLDL, plasma
riglycerides, and the atherogenic index. Comparison be-
ween 2 sets of patients were performed by t test or
ann-Whitney U test. In multivariable logistic regression
nalyses, the independent association of LBP serum levels
ith the likelihood of coronary atherosclerosis was evalu-
ted. The models, fitted for prevalent CAD as dependent
ariable, included age and BMI (model 1), additionally
sCRP and interleukin-6 (model 2), and LDL cholesterol,
ack-years, history of diabetes and/or hypertension, and
erum adiponectin (model 3). For calculation of the odds
atios (ORs), patients were categorized in quartiles based on
ercentiles of the serum LBP concentrations. Interquartile
utoff points of LBP were 14.3 pg/ml (25th percentile), 18.4
g/ml (50th percentile), and 23.4 pg/ml (75th percentile): dategory 1 14.3 pg/ml; 14.3 pg/ml  category
18.4 pg/ml; 18.4 pg/ml  category 3 23.4 pg/ml; and
ategory 4 23.4 pg/ml. Cochran-Armitage trend test for
roportions was used to test for linear trend across categories.
or logistic regression analysis CAD-positive and -negative
atients were included, but not fibromyalgia and sepsis
atients. Values of p  0.05 were considered to be
tatistically significant, except for bivariate correlation
nalyses in which Bonferroni correction for multiple
esting was used, which led to an alpha of 0.003 (per-
ormed using the Statistica software package [StatSoft,
ulsa, Oklahoma]).
esults
aseline characteristics of patients with and without angio-
raphically documented CAD are given in Table 1. In 247
en undergoing elective coronary angiography, CAD was
ound in 172 individuals (69.6%). The individuals with
AD were older and more likely to be current smokers and
ad increased pack-years and LDL cholesterol levels, higher
PG and HOMA-IR, elevated atherogenic index, and
ower HDL cholesterol. Serum LBP levels were signifi-
antly increased in patients with CAD compared with those
ithout CAD (mean 20.6  8.7 pg/ml, median 19.2 pg/ml
s. mean 17.1 6.0 pg/ml, median 17.5 pg/ml, respectively;
 0.002) (Fig. 1). Moreover, when CAD patients were
ompared with septic patients (LBP mean 64.5  32.4
g/ml, median 65.6 pg/ml) and patients with fibromyalgia
LBP mean 14.4  6.0 pg/ml, median 15.0 pg/ml), it was
vident that CAD patients had “intermediate” levels of LBP
hat were statistically significant different from the other
ntities (both p  0.002) (Fig. 1).
Table 2 shows bivariate correlations between cardiovas-
ular risk factors and angiographic scores and serum LBP.
fter Bonferroni correction, LBP levels were significantly
ositively associated with the atherogenic index, pack-years,
nd HOMA-IR. As expected, serum LBP levels were
ighly correlated with markers of systemic inflammation
interleukin-6 r  0.375; hsCRP r  0.497; both p 
.001). In partial correlation analysis, adjusted for age and
MI, the associations between serum LBP and pack-years,
nterleukin-6, and hsCRP remained statistically significant
Table 2).
Table 3 shows multivariable logistic regression models to
stimate the ORs of CAD across quartiles of LBP levels.
fter adjustment for age and BMI, participants in the
ighest compared with the lowest quartile of LBP levels had
significantly increased risk of prevalent CAD (OR 5.444;
5% confidence interval [CI] 2.018 to 14.691; p  0.001;
odel 1). Further adjustment for interleukin-6 and hsCRP
OR 6.072; 95% CI 1.914 to 19.263; p  0.002; model 2)
nd, finally, adjustment for established cardiovascular risk
actors, such as LDL cholesterol, smoking status, history of
iabetes and/or hypertension, and serum adiponectin levels,
id not substantively affect this relationship (OR 5.551; 95%
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Lipopolysaccharide-Binding Protein and CAD July 3, 2007:25–31I 1.602 to 19.227; p  0.007; model 3). Moreover in
ochran-Armitage trend test for proportions, the linear
rend across LBP quartiles was also statistically significant
p  0.001).
The ORs for the presence of CAD in each of the
uartiles based on the serum LBP concentration are also
hown in Figure 2. For clinical translation, cutoff points
ere selected. The BMI- and age-adjusted ORs for CAD in
he second, third, and fourth quartiles for serum LBP were
Clinical Characteristics of Patients With and Wi
Table 1 Clinical Characteristics of Patients
Factor C
Age (yrs)
BMI (kg/m2)
Total cholesterol (mmol/l)
HDL (mmol/l)
LDL (mmol/l)
VLDL (mmol/l)
Triglycerides (mmol/l)
Atherogenic index
Fasting plasma glucose (mmol/l)
HOMA-IR
History of diabetes, n (%)
Current smoker, n (%)
Smoking status (pack-yrs)
Interleukin-6 (pg/ml)
hsCRP (mg/dl)
LBP (pg/ml)
Results are mean SE for parametrically distributed data or median (
CAD () subjects (unpaired t test); †p 0.05; ‡p 0.005 versus CAD
BMI body mass index; HDL high-density lipoprotein; HOMA-IR
C-reactive protein; LBP  lipopolysaccharide-binding protein; LDL lo
Figure 1 Comparison of Serum LBP Levels
Patients with and without incident coronary artery disease (CAD) and control
subjects with fibromyalgia and sepsis. Data are presented as individual values,
and the central line in each column represents the median. p values by Mann-
Whitney U test. LBP  lipopolysaccharide-binding protein.t.593 (95% CI 0.749 to 3.387), 2.138 (95% CI 0.954 to
.343), and 5.444 (95% CI 2.018 to 14.691), respectively,
ompared with the first quartile (Fig. 2).
iscussion
o support the role of innate immunity for the development
f CAD, we investigated whether LBP is associated with
he presence and extent of coronary heart disease in 247
en with clinically stable CAD who underwent elective
oronary angiography.
In patients with angiographically documented CAD, we
ound significantly increased levels of LBP compared with
ngiographically CAD-negative patients. The CAD-
ositive patients were found to have “intermediate” levels of
BP compared with those with sepsis and fibromyalgia.
urthermore, LBP levels showed significant Bonferroni-
orrected correlations with established cardiovascular risk
actors, such as the atherogenic index and pack-years smok-
ng. As we expected on the basis of its physiologic role, LBP
as positively correlated with markers of inflammation,
uch as hsCRP and interleukin-6. When we further ana-
yzed the data by partial correlation analysis, adjusted for age
nd BMI, the associations between LBP and these risk
actors remained statistically significant.
In a multivariable logistic regression analysis, we showed
n estimate for the partial association between LBP and the
resence of CAD. In 3 statistical models, LBP was shown
o be a significant and independent predictor of prevalent
AD. Moreover, the multivariable adjusted OR for CAD
evealed that male patients with increased levels of LBP
23.4 pg/ml) had a 5-fold increase in CAD prevalence.
As mentioned in the preceding, CAD might partly be
Coronary Artery Disease (CAD)
and Without Coronary Artery Disease (CAD)
) (n  172) CAD () (n  75)
2 9.5* 59.0 11.1
8 3.4 27.0 3.5
2 1.24 5.16 1.08
0.83–1.16)† 1.03 (0.90–1.28)
5 1.03* 3.42 0.85
0.36–0.79) 0.48 (0.26–0.78)
1.12–2.10) 1.30 (0.82–2.03)
4.23–6.75)‡ 4.74 (3.83–5.51)
4.90–6.55)† 5.83 (5.45–6.56)
3.65–6.84)‡ 2.49 (1.62–4.84)
15.1) 9 (12.0)
66.3)‡ 30 (40.0)
0–30.0)‡ 11.9 (0–21.3)
1.55–4.72) 2.52 (1.48–4.07)
0.80–3.75) 1.55 (0.70–3.08)
14.9–24.6)‡ 17.5 (12.5–20.2)
artile range) for nonparametrically distributed data. *p 0.05 versus
bjects (Mann-Whitney U test).
stasis model assessment insulin resistance; hsCRP high-sensitivity
ity lipoprotein; VLDL  very low-density lipoprotein.thout
With
AD (
62.
27.
5.4
0.95 (
3.7
0.49 (
1.44 (
5.38 (
5.67 (
4.88 (
26 (
114 (
15.0 (
2.33 (
1.50 (
19.2 (
interqu
() suriggered by subclinical infections, and some studies provide
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July 3, 2007:25–31 Lipopolysaccharide-Binding Protein and CADerologic evidence for the involvement of LPS and
athogen-associated molecular patterns with CAD (6–10).
owever, we want to point out that several studies found no
ssociation between infection and CAD or question this
oncept (11,37,38). We believe that LBP has the advantage
f serving as a sensitive marker for the presence of LPS in
he bloodstream, and our study might stimulate further
ork regarding the role of infectious diseases for CAD.
The nature and physiologic role of LBP has well been
efined (19–21), and LBP has been shown to bind to
ipopolysaccharides, lipoproteins, and lipopeptides (39).
Correlation Coefficients Between Serum Concenof LBP and ronary Risk Factors in Men (n 
Table 2 Correlation Coefficients Between Sof LBP and Coronary Risk Factors i
Variable
Unadjust
r
Age 0.150
BMI 0.124
Total cholesterol 0.128
LDL cholesterol 0.147
HDL cholesterol 0.146
VLDL cholesterol 0.103
Triglycerides 0.127
Atherogenic index 0.212
Pack-years 0.235
HOMA-IR 0.271
History of diabetes 0.032
History of hypertension 0.020
Interleukin-6 0.375
hsCRP 0.497
Severity score 0.133
Extent score 0.088
*p value represents 2-tailed Spearman Correlation coefficients; †p va
significance.
Abbreviations as in Table 1.
ultivariable Logistic Regression Predicting the Likelihood of CADuartiles of LBP Levels, Markers of Systemic Inflammati n, and Es
Table 3 Multivariable Logistic Regression Predicting the LikelihQuartiles of LBP Levels, Markers of Systemic Inflamma
Variable
Model 1
Exp(B) 95% CI Exp(B) p Exp
LBP 0.003*
Quartile 1 1.000 1.0
Quartile 2 1.539 0.749–3.387 0.385 1.4
Quartile 3 2.138 0.954–4.343 0.156 1.9
Quartile 4 5.444 2.018–14.691 0.001* 6.0
Age 1.027 0.998–1.057 0.068 1.0
BMI 1.096 0.999–1.203 0.053 1.0
hsCRP† 0.6
Interleukin-6† 1.0
LDL cholesterol
Pack-years
History of diabetes
History of hypertension
Adiponectin†
c index 0.652
BP quartiles: category 114.3 pg/ml; 14.3 pg/ml category 218.4 pg/ml; 18.4 pg/ml cate
ariables.
Abbreviations as in Table 1.mong a variety of ligands, oxidized LDL leads to up-
egulation of TLR-4 (15), and subsequently the activation
f innate immunity leads to up-regulation of LBP synthesis
n the liver, mainly via interleukin-1 and -6 (40). We
ropose LBP as an additional marker for CAD risk, because
BP can be regarded as a surrogate marker for activated
nnate immune system, which plays an important role in the
athophysiology of atherosclerosis. By comparing levels of
BP with septic patients and patients with fibromyalgia, we
ould show that CAD patients had “intermediate” levels of
BP which were different from critically ill patients and
ons
Concentrations
n (n  247)
Adjusted for Age and BMI†
p Value r p Value
0.020 — —
0.054 — —
0.047 0.124 0.056
0.024 0.135 0.039
0.024 0.120 0.065
0.113 0.084 0.200
0.051 0.131 0.044
0.001‡ 0.165 0.011
0.001‡ 0.207 0.001‡
0.001‡ 0.178 0.012
0.618 0.030 0.644
0.753 0.041 0.532
0.001‡ 0.287 0.001‡
0.001‡ 0.453 0.001‡
0.041 0.080 0.219
0.174 0.038 0.587
resents partial correlation analysis; ‡Bonferroni-corrected statistical
rding tohed Cardiovascular Risk Factors
of CAD According to
and Established Cardiovascular Risk Factors
Model 2 Model 3
95% CI Exp(B) p Exp(B) 95% CI Exp(B) p
0.017* 0.046*
1.000
0.640–3.276 0.374 1.535 0.610–3.862 0.363
0.876–4.476 0.101 2.083 0.849–5.110 0.109
1.914–19.263 0.002* 5.551 1.602–19.227 0.007*
1.004–1.068 0.026* 1.044 1.009–1.080 0.014*
0.993–1.215 0.069 1.039 0.931–1.160 0.497
0.286–1.422 0.271 0.435 0.177–1.066 0.069
0.385–3.078 0.874 0.609 0.194–1.913 0.396
1.011 1.000–1.022 0.057
1.025 1.005–1.046 0.013*
0.994 0.378–2.618 0.991
3.158 1.545–6.457 0.002*
0.225 0.066–0.769 0.017*
0.673 0.767
23.4 pg/ml; and category 423.4 pg/ml. *Statistical significance (p 0.05); †log-transformedtrati247)
erum
n Me
ed*




lue repAccotablis
ood
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(B)
00
48
80
72
35
98
38
88
gory 3
f
t
i
b
p
b
o
i
W
n
b
d
p
p
e
i
h
i
r
s
b
a
t
fi
e
i
r
a
t
t
g
A
T
B
p
B
R
D
B
R
1
1
30 Lepper et al. JACC Vol. 50, No. 1, 2007
Lipopolysaccharide-Binding Protein and CAD July 3, 2007:25–31rom patients that can be regarded to be in a noninflamma-
ory state. Furthermore, within the CAD group, LBP levels
ncreased with the severity of coronary heart disease, possi-
ly reflecting a more widespread inflammation in those
atients. Because LBP serum levels showed some overlap
etween groups, which might be caused by an imprecision
f the currently used test, automation of the test procedure
s highly desirable to reduce this imprecision of the marker.
ith a lower imprecision and further reduction of analytic
oise, it can be assumed that an even better separation
etween groups is possible.
Interestingly, in multivariable analysis, LBP was indepen-
ent of interleukin-6 and hsCRP levels in predicting the
revalence of CAD. Of course, elevated hsCRP is a strong
redictor of future cardiovascular risk in patients with
stablished CAD, with or without a previous myocardial
nfarction. Blake and Ridker (41) have shown that elevated
sCRP can predict risk of adverse cardiovascular events,
ncluding death, acute myocardial infarction, and need for
evascularization procedures, in patients with acute coronary
yndromes. Lipopolysaccharide-binding protein has not
een thoroughly investigated regarding its potency in being
cardiovascular risk factor yet. Nevertheless, on the basis of
he present data and theoretic considerations LBP might
nd its mechanistic role in coronary plaque development.
In conclusion, the present study is the first to report that
levated levels of circulating LBP represent a strong and
ndependent predictor of the presence of CAD in men. The
esults indicate that the measurement of serum LBP may be
useful risk marker for CAD that needs further investiga-
ion in prospective trials. Novel drugs might use targets of
he innate immune system, such as LBP, to offer a patho-
Figure 2 Odds Ratio for CAD
The second, third, and fourth quartiles compared with the first quartile of lipopolys
adjusted for age and body mass index. Vertical bars indicate 95% confidence inteenetically orientated treatment to lower cardiovascular risk.cknowledgments
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